Supriya Lifescience Limited posted strong Q3 FY26 results with revenue from operations at INR 2.06 billion and net profit at INR 496.8 million. The company reported 11% revenue growth, 9% EBITDA growth, and highlighted new product launches, capacity utilization, and strategic land acquisitions to drive future expansion.
Supriya Lifescience Limited announced its financial results for the quarter ended December 31, 2025, showcasing steady growth and strategic initiatives that strengthen its market position.
Key Highlights
-
Revenue from operations stood at INR 2,064.4 million, reflecting 11% year-on-year growth
-
Net profit reached INR 496.8 million, supported by strong product pipeline performance
-
EBITDA rose 9% to INR 720.8 million, though margins narrowed due to higher employee and operational costs
-
Capacity utilization maintained at 76%, ensuring efficient production levels
-
Successful launches in cardiovascular and ADHD therapeutic segments boosted portfolio diversity
-
Strategic land acquisitions exceeding 117,000 sq. mt. to support backward integration and expansion plans
-
R&D investments continued with four new process patents filed, reinforcing innovation-driven growth
-
Board approved re-appointment of Dr. Neelam Yashpal Arora and appointed Mr. Manish Panchal and Mr. Kothandaraman Hari as additional independent directors, strengthening governance
Supriya Lifescience’s Q3 FY26 performance reflects resilience in a competitive pharmaceutical landscape, with a clear focus on innovation, expansion, and operational efficiency.
Sources: ScanX News, InvestyWise, Mint